Sautter L, Hofheinz R, Tuettenberg J, et al. - Researchers examined the clinical efficacy of imatinib in patients with newly diagnosed and recurrent glioblastoma in combination with radiotherapy. In a nonrandomized, 2-arm, open-label phase 2 trial, they included 51 patients (aged 18 years or older; with an ECOG performance status of 0–2) that were either newly diagnosed (arm A; n = 19) with a measurable tumor (ie, after incomplete resection or biopsy) or that were diagnosed with progression of a glioblastoma after initial therapy (arm B; n = 32). They administered 600 mg/day imatinib in combination with hypofractionated radiotherapy (2.5 Gy per fraction, 22 fractions) to patients in arm A. Either 600 mg/day imatinib alone or in combination with re-irradiation at various doses was provided to patients in arm B. During the median follow-up of 4 (0.5–30) months in arm A and 6.5 (0.3–51.5) months in arm B, they observed no measurable activity of imatinib in patients with newly diagnosed or recurrent glioblastoma.